New Horizon Medical Solutions
Provider of biologic wound‑care products and turnkey practice optimization services. The company supplies amniotic and placental tissue allografts and acellular dermal grafts, offers full revenue‑cycle/billing services, EHR/inventory integrations, clinical education, and reimbursement support for outpatient, surgical and wound care providers.
Industries
Nr. of Employees
small (1-50)
New Horizon Medical Solutions
Products
Lyophilized amniotic membrane allografts
Shelf‑stable amniotic membrane grafts in flexible sizes for treatment of acute and chronic wounds.
Dual‑layer and multi‑layer amniotic membrane grafts
Thicker, multi‑layer membrane formats engineered for structural support and moisture retention in complex wounds.
Dehydrated placental and chorionic membrane allografts
Dehydrated placental/chorionic membrane grafts designed for homologous clinical use without refrigeration.
Acellular dermis grafts
Acellular human dermis grafts processed with validated sterilization methods for surgical reconstruction and wound applications.
Membrane wraps and surgical scaffold formats
Sterile membrane wraps and scaffold products for surgical and post‑trauma wound protection that preserve ECM integrity.
Lyophilized amniotic membrane allografts
Shelf‑stable amniotic membrane grafts in flexible sizes for treatment of acute and chronic wounds.
Dual‑layer and multi‑layer amniotic membrane grafts
Thicker, multi‑layer membrane formats engineered for structural support and moisture retention in complex wounds.
Dehydrated placental and chorionic membrane allografts
Dehydrated placental/chorionic membrane grafts designed for homologous clinical use without refrigeration.
Acellular dermis grafts
Acellular human dermis grafts processed with validated sterilization methods for surgical reconstruction and wound applications.
Membrane wraps and surgical scaffold formats
Sterile membrane wraps and scaffold products for surgical and post‑trauma wound protection that preserve ECM integrity.
Services
End‑to‑end billing services including coding, claims submission, denial management, appeals and patient billing to improve reimbursement and cash flow.
Assessments and implementations to improve scheduling, workflow, staffing, documentation, SOPs and operational efficiency.
Hands‑on training, usage protocols, SOPs and documentation to support safe adoption of biologic products and clinical workflows.
Coding guidance, coverage verification, documentation support, and payer engagement to improve reimbursement for biologic therapies.
Operational support, payment terms and product onboarding services for distributors and clinic networks.
End‑to‑end billing services including coding, claims submission, denial management, appeals and patient billing to improve reimbursement and cash flow.
Assessments and implementations to improve scheduling, workflow, staffing, documentation, SOPs and operational efficiency.
Hands‑on training, usage protocols, SOPs and documentation to support safe adoption of biologic products and clinical workflows.
Coding guidance, coverage verification, documentation support, and payer engagement to improve reimbursement for biologic therapies.
Operational support, payment terms and product onboarding services for distributors and clinic networks.
Expertise Areas
- Advanced wound care and skin substitutes
- Regenerative medicine biologics
- Revenue cycle management and medical billing
- Practice optimization and clinical workflow design
Key Technologies
- Amniotic/placental membrane allografts
- Lyophilization and dehydration processing
- Acellular dermis processing
- Tissue sterilization processes
News & Updates
Announcement of a new tri‑layer matrix product for wound care (product launch and portfolio expansion).
Breaking ground on a U.S. biologics manufacturing facility to expand wound care manufacturing capacity.
Addition of a next‑generation amnio‑chorionic membrane product to the company's portfolio.
Announcement of a new tri‑layer matrix product for wound care (product launch and portfolio expansion).
Breaking ground on a U.S. biologics manufacturing facility to expand wound care manufacturing capacity.
Addition of a next‑generation amnio‑chorionic membrane product to the company's portfolio.